Pharmaceuticals

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

New 2- and 3-year data shows lebrikizumab sustains skin clearance with less frequent dosing, offering patients flexibility and positioning Eli Lilly for a major market share.

Cosmos Health secures 25M+ unit orders, projecting a $10M profit from its Greek facility. A bold manufacturing play to stabilize its finances.

With a new brand and $1B in state funding, Indiana is unifying its massive bioscience sector to challenge global hubs like Boston. Is 'BioHeartland' the real deal?

A projected 12.4% CAGR signals a boom in hematopoietic stem cell transplantation, but the real story lies in the science poised to overcome timeless hurdles.

A decade of new science has prompted the FDA to overhaul testosterone therapy rules, erasing old fears and unlocking a multi-billion dollar market for aging men.

A new pharma deal isn't just about medicine. It's about the AI-driven network set to dismantle the slow, costly system of drug discovery as we know it.

With a pivotal drug approval on the horizon, Spruce Biosciences' appointment of a rare disease veteran signals a critical transition from R&D to commercial reality.

MapLight's Phase 2 trial for ASD missed its primary goal, but a powerful signal in reducing irritability in teens could reshape its future and offer a safer alternative.

A new prostate cancer drug is emerging from a powerful alliance. We deconstruct the strategic rationale behind the deal, revealing a model for the future.

A single drug receptor could treat cancer, psoriasis, and liver disease. Can-Fite’s new scientific validation boosts its platform, but clinical and financial hurdles loom.

A Chinese AI innovator and a new European biotech just sealed a massive deal. It’s a blueprint for the future of medicine, where technology and strategy unite for patients.

Merck's positive Phase 3 results for tulisokibart signal a new era for UC care, targeting both fibrosis and inflammation in a potential first-in-class win.

Sanofi taps AI-native biotech expert Paulo Fontoura to lead its global R&D, a high-stakes move to accelerate drug discovery after recent pipeline disappointments.

A new index reveals pharma's $8B ad spend fails to buy AI visibility. Eli Lilly and Novo Nordisk lead as AI follows patient research, not TV spots.

With no approved drugs for the Bundibugyo Ebola outbreak, 101 Therapeutics releases un-reviewed data, forcing a global health showdown between speed and safety.

Straive's acquisition of NextGen Invent isn't just another deal; it's a strategic strike to dominate the AI operationalization market. Here's why.

At BIO 2026, Fapon Group unveils a novel strategy combining T-cell engagers and in vivo CAR-T to target complex diseases. What does this mean for the future?

As global supply chains shift, a conference in Montreal highlights a crucial trade realignment. But are Canadian firms ready to seize the massive EU opportunity?

Replicate Bioscience’s new Gates Foundation grant isn't just about funding; it's a strategic move to deploy novel srRNA technology for global vaccine equity.